MannKind Corporation (MNKD) Income Statement

The 42.9% YoY growth in 2026Q2 represents a sharp acceleration from the 15.1% in 2026Q1 and 5.7% in 2025Q2, suggesting the United Therapeutics partnership is scaling rapidly. This growth appears to be driven by high-margin royalty income rather than low-margin product sales, as gross margin improved to 73.0% despite revenue mix shifts. The durability of this trajectory hinges on continued Tyvaso DPI prescription growth and the absence of competitive disruption from Liquidia's treprostinil formulations.

The slight sequential decline in gross margin may indicate higher manufacturing costs or a temporary product mix shift, but the 82.47% reported gross margin in the broader context suggests structural support from Tyvaso DPI royalties. Compared to peers like UTHR (87.9%) and ACAD (91.7%), MNKD's gross margin is lower, but it benefits from a high-margin collaboration stream that could expand as royalty volumes grow. Investors should monitor whether Afrezza's direct costs or inventory write-offs pressure margins in coming quarters.

The dramatic deterioration in operating margin from 28.5% in 2025Q1 to -0.3% in 2026Q2 suggests that SG&A and R&D expenses have outpaced revenue growth, with SG&A jumping to $58.3M in 2026Q2 from $25.0M in 2025Q1. This may reflect increased investment in the Afrezza sales force or one-time costs related to the 2026 catalysts, but it undermines the narrative of scaling profitability. The modest 11.1% operating margin in recent quarters indicates limited buffer against cost inflation, and the company's ability to regain operating leverage is critical.

The sharp rise in SG&A, which more than doubled from 2025Q1 levels, suggests aggressive investment in commercial infrastructure, likely for Afrezza and Tyvaso DPI support. R&D also increased to $18.0M in 2026Q2 from $13.7M in 2025Q2, reflecting pipeline advancement, but the combined cost growth is eroding operating income. Management's expense discipline will be tested as they balance growth investments against the need to achieve sustainable profitability.